<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605497</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00021775</org_study_id>
    <nct_id>NCT04605497</nct_id>
  </id_info>
  <brief_title>Time-in-range Using Continuous Glucose Monitoring Management of Gestational Diabetes Mellitus</brief_title>
  <official_title>A Single Center Open-label Randomized Control Pilot Study to Assess the Efficacy of Real-time Continuous Glucose Monitoring in Subjects With Gestational Diabetes to Increase Glucose Time-in-range</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The continual glucose is going to increase time-in-range compared to the standard method in&#xD;
      women with gestational diabetes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average time-in-range over a 24 hour period</measure>
    <time_frame>From enrollment to10 days after discharge from hospital following delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average time-in-range during waking hours</measure>
    <time_frame>From enrollment to10 days after discharge from hospital following delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average time-in-range while asleep</measure>
    <time_frame>From enrollment to10 days after discharge from hospital following delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of Dexcom G6 real-time CGM to monitor blood glucose levels continually.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Referent Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Self-capillary blood glucose monitoring (SCBG) testing 4x/day with blinded CGM every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Continuous glucose monitoring (CGM)</intervention_name>
    <description>Continual use of CGM to monitor blood glucose levels from enrollment through delivery admission &amp; discharge + additional 10 days during postpartum period</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Self-Capillary Blood Glucose Monitoring (SCBG)</intervention_name>
    <description>Conventional SCBG 4x/day testing (standard care in Oregon; fasting and 1-hour postprandial) with blinded CGM every 2 weeks SCBG 4 times/day until delivery admission 10 days duration with each blinded CGM wear</description>
    <arm_group_label>Referent Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-55 years&#xD;
&#xD;
          -  Singleton pregnancy â‰¥20 weeks gestation&#xD;
&#xD;
          -  Diagnosed with GDM by either 1-step (IADPSG) or 2-Step (Carpenter-Coustan)&#xD;
&#xD;
          -  Compatible, validated phone and operating system to support Dexcom G6 CGM App (See&#xD;
             Supplementary Table 1) or option to use receiver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic immunosuppression&#xD;
&#xD;
          -  Concomitant disease or condition that may compromise patient safety or the ability to&#xD;
             complete study tasks including and not limited to: severe mental illness or a&#xD;
             diagnosed or suspected eating disorder&#xD;
&#xD;
          -  Known allergy to medical grade adhesives&#xD;
&#xD;
          -  Pre-gestational diabetes&#xD;
&#xD;
          -  Multifetal gestation&#xD;
&#xD;
          -  Current alcohol or illicit drug use&#xD;
&#xD;
          -  Simultaneous participation in another clinical study with investigational medicinal&#xD;
             product(s) that might have an impact on the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Valent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Women's Health Research Unit Department of Ob/Gyn</last_name>
    <phone>503-494-3666</phone>
    <email>whru@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Valent</last_name>
      <email>valent@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Amy Miyoshi Valent</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>pregnancy</keyword>
  <keyword>gestational diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

